Pharmaceutical Policy Updates Effective June 1, 2020

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at **mvphealthcare.com** and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy.
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs.
- **Review/No Changes**– Policies that have been reviewed but have no content change.
- **Archived** – Denotes a policy that is no longer active.

The following policies are effective June 1, 2020 and will be available for viewing on or before April 1, 2020. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Valchlor	Updated
Onychomycosis	Updated
Diclofenac (topical) Products	No changes
Topical Agents for Pruritus	No changes
Lidocaine (topical) Products	No changes
Select Injectables for Asthma	Updated
Infliximab – effective 4/1/20	Updated
Pharmacy Management Programs	Updated
Weight Loss Agents – effective 4/1/20	Updated
Calcitonin Gene-Related Peptide (CGRP) Antagonist	Updated
Agents for Female Sexual Dysfunction	Updated
Drug Utilizing Review and Monitoring Program – effective 4/1/20	Updated
Acthar	No changes
Patient Medication Safety	No changes
Cosmetic Drug Agents	No changes
Eskata	No changes
Parsabiv	No changes
Experimental or Investigational Procedures, Behavioral Health Services, Drugs and Treatments, Off-Label use of FDA Drugs and Clinical Trials – effective 2/1/20	Updated

To view a summary of all updates, visit **mvphealthcare.com/Providers/COVID19.**

To receive future FastFax messages by email, send a request to **MVPFastFax@mvphealthcare.com**.

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at **1-800-684-9286.**